ApoPharma Inc Toronto

Toronto, Canada

ApoPharma Inc Toronto

Toronto, Canada
SEARCH FILTERS
Time filter
Source Type

Fradette C.,ApoPharma Inc Toronto | Rozova A.,ApoPharma Inc Toronto | Stilman A.,ApoPharma Inc Toronto | Tsang Y.C.,ApoPharma Inc Toronto | And 2 more authors.
Clinical Pharmacology in Drug Development | Year: 2017

This study evaluated whether deferiprone, an oral iron chelator, acts to prolong the QT interval. Fifty healthy volunteers received single doses of each of the following: therapeutic dose of deferiprone (33 mg/kg), supratherapeutic dose (50 mg/kg), placebo, or moxifloxacin, a positive control known to significantly prolong QT interval. Following each dose, subjects underwent cardiac monitoring, pharmacokinetics assessments, and safety assessments. Based on the QT interval obtained using the Fridericia correction for heart rate (QTcF), the upper bound of the 1-sided 95% confidence interval of the mean difference between deferiprone and placebo was <10 milliseconds (the threshold of concern defined by authorities) at all time points for both doses: maximum difference of 3.01 milliseconds for the therapeutic dose and 5.23 milliseconds for the supratherapeutic dose. The difference in dQTcF between moxifloxacin and placebo demonstrated that the study was adequately sensitive to detect a significant prolongation of QTcF. The concentration-response correlation analyses revealed some weak but statistically significant trends of increase in dQTcF and ddQTcF with increasing exposure to deferiprone, but these trends should have no clinical consequence even at the recommended maximum dosage. In conclusion, there was no clinically meaningful effect on QTc interval following single therapeutic or supratherapeutic doses of deferiprone. © American College of Clinical Pharmacology.

Loading ApoPharma Inc Toronto collaborators
Loading ApoPharma Inc Toronto collaborators